Estimated read time: 1-2 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
LOS ANGELES (AP) — The Latest on the arraignment of a man suspected of providing Mac Miller the drugs that killed the rapper in September 2018 (all times local):
11:40 a.m.
A man charged with selling rapper Mac Miller the drugs that killed him last year has pleaded not guilty.
Cameron Pettit entered the plea Thursday in federal court in Los Angeles.
He stood alongside his attorney and spoke only to answer a judge's questions.
Prosecutors allege the 28-year-old sold Miller cocaine and pills that contained the powerful opioid fentanyl two days before the 26-year-old rapper died of an accidental overdose in September 2018.
Pettit, who has been in custody since his Sept. 4 arrest, faces a mandatory minimum sentence of 20 years in federal prison if convicted of a charge related to Miller's death.
Two others, who prosecutors say acted as supplier and messenger to Pettit, have also been charged in the case. It's not clear when they'll be arraigned.
___
12 a.m.
A man charged with selling rapper Mac Miller the drugs that killed him last year is set to appear in federal court in Los Angeles.
Prosecutors allege 28-year-old Cameron Pettit of West Hollywood sold Miller counterfeit opioids and cocaine. He's scheduled to be arraigned Thursday.
Pettit, who has been in custody since his arrest last month, has not entered a plea. His attorney has declined comment.
He faces a mandatory minimum sentence of 20 years in prison if convicted of either of the charges related to Miller's death.
Two others have been arrested in the case. It's unclear when they will be arraigned.
Authorities say the 26-year-old Miller died in September 2018 of an accidental overdose of the opioid fentanyl, along with cocaine and alcohol.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
